Skip to main content
Fig. 3 | Arthritis Research & Therapy

Fig. 3

From: Validation in the ESPOIR cohort of vitamin K-dependent protein S (PROS) as a potential biomarker capable of predicting response to the methotrexate/etanercept combination

Fig. 3

Determination of concentration threshold for PROS using receiver operating characteristic (ROC) from data of the ESPOIR cohort prior to treatment with etanercept/methotrexate or adalimumab/methotrexate. a ROC curve averaging of PROS prior to MTX/ETA treatment (left) or MTX/ADA combination (right). Gray line corresponds to 95% confidence interval. Black arrow corresponds to our best threshold (40 μg/mL). b Table showing the different parameters resulting from ROC curve analysis for each drug combination (MTX/ETA or MTX/ADA)

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us